Foundation for NIH Facilitated Partnership Announced Availability of Alzheimer’s Genome Biomarker Data

Filed in archive Alzheimer's Disease , Diagnostics , Information About , Studies on March 19, 2009

The genome biomarker data for the Alzheimer's Disease Neuroimaging Initiative (ADNI) is ready to be shared with scientists world-wide for further analysis. Such were the announcement of the Foundation for the National Institutes of Health, the convener of a $60 million public-private partnership that was begun by the National Institute on Aging (NIA), and supported by the National Institutes of Health and the Food and Drug Administration along with more than 20 private-sector companies and organizations.

This ongoing $60 million, 6-year ADNI study is the most comprehensive effort to date to identify brain and other biological changes associated with memory decline, and it will provide the most extensive and robust dataset of its kind in the Alzheimer's disease field.

The availability of such genome biomarker data may be able to elucidate the 'mystery' that is Alzheimer's disease. There is no cure for Alzheimer's disease making it one of the most gruelling brain injury rehabilitation programmes available from a healthcare professional

Read more info here.